A Closer Look at Immunotherapy in the First Line Management of Metastatic Bladder Cancer: Maintenance Options for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

Recent Therapeutic Advances in the Management of Metastatic Bladder Cancer: Managed Care Perspectives on Immunotherapy in the First Line Setting is a three-part webinar series

This is Part 1 of the series focusing on first line management of metastatic bladder cancer

This activity is an archive from the webinar held January 27, 2021

This activity is valid from March 1, 2021 to March 1, 2023
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Pfizer

Description:
Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. According to the American Cancer Society, there will be 80,470 new cases of bladder cancer and 17,670 deaths in the United States in 2020. Before the advent of new treatments in recent years, the basic management of this illness has remained unchanged for decades. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. As the role of the immune system in oncogenesis and therapy has become clearer across cancer types, new approaches emerged with important benefits in metastatic bladder cancer, which led to the introduction of immune checkpoint inhibitors. However, when those options fail, options are sparse to manage this difficult disease. Fortunately for patients with metastatic bladder cancer, new agents, including antibody-drug conjugates, have recently emerged for patients who have failed on immunotherapy and chemotherapy. It is for this reason that medical directors, oncologists, practicing physicians, nurse case managers and other healthcare professionals must be educated on these emerging options and strategies for their implementation into the treatment paradigm, which will ultimately improve patient outcomes in the metastatic bladder cancer patient population.

While immunotherapy has revolutionized care for metastatic bladder cancer, it doesn't work for everyone. Patients who progress with or fail immunotherapy will need subsequent therapy, and there is limited data to guide treatment selection. New data from late-stage clinical trials introduce emerging targeted agents with great promise in improving outcomes for these patients. As these options have recently become available and shown the ability to improve outcomes in patients with this difficult to treat disease, it is imperative that physician medical directors, oncologists, practicing physicians, nurse case managers and other healthcare professionals are brought up to date regarding these novel treatments, so that they can properly approve and select therapy based on individual patient characteristics for improved clinical and economic outcomes.

Upon completion of this activity, participants will be able to:

  • Identify current unmet clinical and economic needs in the management of metastatic bladder cancer and evidence-based recommendations for the care of patients with these tumors

  • Examine recent clinical data on the safety and efficacy of immune checkpoint inhibitors in the management of metastatic bladder cancer in the first line setting

  • Assess recent evidence on the role of maintenance immunotherapy in the first line management of metastatic bladder cancer

  • Explore the role of sequential therapy and the differences between upfront treatment and sequencing strategies with immune checkpoint inhibitors in metastatic bladder cancer

  • Identify patients with metastatic bladder cancer who would potentially benefit from immunotherapies, in first line maintenance settings or beyond

     

Faculty: Petros Grivas, MD, PhD
Physician, Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington School of Medicine

Disclosure:

Dr. Grivas has served as a consultant within the past 24 months for AstraZeneca, BMS, Clovis Oncology, Genentech/Roche, Merck, Immunomedics, Mirati Therapeutics, Foundation Medicine, Bayer, Exelixis, Genzyme, GlaxoSmithKline, EMD Serono, Pfizer, Janssen, Seattle Genetics, and Dyania Health. He has received grant research funding to his institution within the past 24 months from Bavarian Nordic, Clovis Oncology, Debiopharm, Immunomedics, Merck, Pfizer, QED Therapeutics, GlaxoSmithKline, KureIT Cancer Research, and BMS. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from Pfizer

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue